Biomarkers that predict musculoskeletal response to anabolic therapies should expedite drug development. During collagen synthesis in soft lean tissue, N-terminal propeptide of type III procollagen (P3NP) is released into circulation. We investigated P3NP as a biomarker of lean body mass (LBM) and muscle strength gains in response to testosterone and GH.
kers that predict anabolic response to function promoting therapies would be of enormous value in the initial screening of candidate molecules. Indeed, biomarker discovery has been deemed a priority area of research by the National Institutes of Health. Here we describe the application of N-terminal propeptide of type III procollagen (P3NP) as a biomarker of anabolic response to supplementation with testosterone and GH in older persons.
Type III collagen in soft connective tissues, such as muscle and skin, is synthesized from larger procollagen III molecules that carry peptide extensions at both N-and C-terminal ends (2) (3) (4) . The N-and C-terminal extensions of procollagen III are removed by specific proteinases during final stages of collagen synthesis and released into circulation in stoichiometric amounts (4) . P3NP, a product of this proteolytic cleavage during collagen synthesis in connective tissue, can be measured in the human serum, and its circulating concentrations have been described in children, healthy adults, acromegalics, and athletes (5) (6) (7) (8) (9) . P3NP levels are responsive to exercise, testosterone, and GH (6, 10 -14) and are being explored as a marker of GH doping in sports (5, 6, 10, 12, 14 -17) . Based on the stoichiometric relationship between collagen synthesis and P3NP release during soft tissue generation (4), we hypothesized that changes in circulating P3NP concentrations would reflect gains in lean body mass (LBM) and appendicular skeletal muscle mass (ASM) during administration of anabolic therapies, such as testosterone and GH. Accordingly, we measured circulating P3NP concentrations at baseline and in response to administration of testosterone and recombinant human GH (rhGH) in community-dwelling older men, who participated in the Hormonal Regulators of Muscle and Metabolism in Aging (HORMA) trial (18, 19) .
The HORMA trial, whose design and main findings have been published (18, 19) , was a multicenter study of older, community-dwelling men who had levels of testosterone and IGF-I typical of their age and who received graded doses of testosterone gel either alone or in combination with placebo or one of two physiological doses of rhGH. Testosterone and rhGH administration were each associated with significant gains in LBM and ASM (18) . We tested the hypothesis that increase in P3NP is associated with gains in LBM and ASM during testosterone and rhGH administration. We also determined whether early changes in P3NP at 4 wk were predictive of changes in LBM and ASM at the end of treatment (16 wk).
Subjects and Methods
The protocol was approved by the Institutional Review Boards at University of Southern California, Tufts University, Charles Drew University, and Washington University. All participants provided written informed consent.
We recruited community-dwelling men, 65-90 yr old, who had serum IGF-I levels in the lower tertile for adults (Ͻ167 ng/ml; 21.9 nmol/liter; Quest Diagnostics, San Juan Capistrano, CA) and morning total testosterone level in the lower half (150 -550 ng/dl; 5.21-19.1 nmol/liter) of adult male range (18, 19) . The participants were required to have prostate-specific antigen of 4.0 ng/ml or less, hematocrit of 50% or less, and fasting blood glucose less than 126 mg/dl (6.99 mmol/liter).
Study interventions
All participants were treated monthly starting on the day of randomization with a long-acting GnRH agonist (leuprolide acetate depot, 7.5 mg im; TAP Pharmaceuticals, Deerfield, IL) to suppress endogenous testosterone production. The participants were randomly assigned from computer-generated randomization tables to one of six treatment groups to receive either 5 g (groups A-C) or 10 g (groups D-F) of 1% testosterone transdermal gel (Solvay Pharmaceuticals, Marietta, GA) with or without 0, 3, or 5 g/kg rhGH (groups A/D, B/E and C/F, respectively; Genentech, South San Francisco, CA). Testosterone gel was applied daily transdermally and rhGH was administered by sc injection each evening.
The 5-and 10-g doses of testosterone were chosen to produce a spectrum of serum levels via the Leydig cell clamp that would be in the low normal range typical of older men or mid-to high normal levels typical of younger men, respectively (20) . The 3 g/kg dose of rhGH was chosen because 3.3 but not 2.0 g/kg ⅐ d has increased whole-body protein synthesis in GH-deficient adults (21) . The 5 g/kg ⅐ d dose was chosen to produce a greater anabolic stimulus but was expected to be low enough to minimize adverse effects that have occurred with higher doses (22, 23) . Testosterone and rhGH were administered for 16 wk.
Outcome measures
LBM and ASM were measured by dual-energy x-ray absorptiometry at baseline and during wk 16, as described (18) . Composite strength was measured by the one-repetition maximum method (24, 25) for muscle groups of upper and lower extremities and reported as percent change from baseline (18) . Screening testosterone was determined by RIA in the clinical laboratories of the participating centers. After study completion, stored samples were batch tested by liquid chromatography tandem mass spectrometry method with a sensitivity of 2 ng/dl and interassay coefficient of variation (CV) of 4 -8% (26, 27) . Serum IGF-I levels were measured by an immunoassay in University of Southern California General Clinical Research Center Endocrine Laboratory (18) .
Serum P3NP concentrations were measured by a validated equilibrium RIA (28) by Pacific Biometrics, Inc. (Seattle, WA) using a UniQ PIIINP RIA kit (Orion Diagnostica, Espoo, Finland). The blood for P3NP measurement was collected in red top tubes, centrifuged within 20 min, and immediately frozen at Ϫ80 C. The samples were not thawed until the time of the assay. Two hundred microliters serum were incubated with 200 l of iodinated P3NP tracer and 200 l of diluted anti-P3NP antibody for 2 h at 37 C. Immune complexes were separated by addition of 500 l second antibody for 30 min at room temperature (28) . The sensitivity of the assay was 0.2 ng/ml. The reference range in adult men and women is 2.3-6.4 ng/ml. Intraassay CVs were 23.0, 7.0, and 4.1% at P3NP concentrations of 2.8, 6.6, and 11.9 ng/ml, respectively, and interassay CVs were 6.5, 4.5, and 7.2% at P3NP concentrations of 2.7, 6.8, and 12.2 ng/ml, respectively (28) .
Statistical analyses
Analyses were conducted for 106 evaluable men who completed 16 wk of treatment and had complete P3NP data. Baseline characteristics were compared across groups using one-way ANOVA for continuous variables (e.g. age, hormones, body composition, and P3NP) and 2 analyses for discrete variables (e.g. ethnicity/race). If the distribution of a continuous variable was nonnormal, then Kruskal-Wallis nonparametric ANOVA was used. Changes in P3NP levels at 4, 8, and 16 wk were compared across groups using one-way ANOVA and the Wald test for trend. When significant group differences were found, pairwise comparisons were made using the Tukey's procedure. Paired t tests were used to compare within-group 4-, 8-, and 16-wk changes from baseline.
Correlation analyses were conducted to assess the univariate relationship of temporal changes at 4, 8, and 16 wk in P3NP with the temporal changes in LBM, ASM, and testosterone levels and IGF-I levels. The distributions of temporal changes of LBM, ASM, testosterone, and IGF-I were stratified at the median into low and high responders. Student t tests were conducted to contrast the temporal changes in P3NP between low vs. high responders for LBM, ASM, testosterone, and IGF-I.
Separate stepwise linear regression analyses were conducted to identify the order of independent predictors of 16-wk change in LBM, ASM, or P3NP. In these analyses, we included independent variables that were associated with the dependent variable at P Ͻ 0.20 in univariate analyses. Thus, in models to identify predictors of 16-wk change in P3NP, candidate independent variables included age at baseline and 16 wk changes in LBM, ASM, and change in testosterone and IGF-I levels. In addition, logistic regression analysis was performed for each quartile of change in LBM at each time point (4, 8, and 16 wk) for high P3NP responders (based on the change in P3NP at wk 4, 8 or 16 being greater than the median response). Similar analyses were conducted for each quartile of change in ASM. Student t tests and logistic regression analyses were performed to compare the changes in P3NP at each time point between subgroups defined by low and high changes in testosterone and low and high changes in IGF-I.
We estimated the minimal clinically important difference (MCID) of change in P3NP concentrations that was associated with 1 kg gain in LBM and 0.5 kg gain in ASM. Rather than determining the MCID estimates from a single regression analysis using all 106 participants, we used the bootstrapping approach to obtain more robust estimates of MCIDs. We generated 1000 bootstrap samples, in which each bootstrap sample set contained 90% of the original sample (96 men) randomly drawn from the original 106 men without replacement. For each bootstrap sample, we estimated the two MCID estimates using regression analyses. The most reliable MCID estimates were the average of the 1000 bootstrap estimates, along with 95% confidence interval. Statistical analyses were carried out using the Statistical Analysis System 9.1 (SAS Institute Inc., Cary, NC).
The study was designed to test the primary hypotheses with 80% power (18) . For secondary analyses described in this manuscript, we assessed the adequacy of the sample size by determining the detectable effect size or the detectable correlation coefficient at the 80% power level. For evaluating the temporal changes in P3NP levels between high and low responders based on LBM, ASM, and hormone levels, a sample size of 50 in each group has 80% power to detect an effect size of 0.57 using a two-group t test with a 0.05 two-sided significance level. For evaluating the temporal changes in P3NP levels between high quartile and low quartile responders based on LBM, ASM, and hormone levels, a sample size of 25 in each group has 80% power to detect an effect size of 0.81 using a two-group t test with a 0.05 two-sided significance level. The minimum detectable correlational relationship between change in P3NP and changes in LBM and ASM with sample size of 106 is 0.3, with 80% power at 0.05 two-sided significance level.
Results
The baseline characteristics of the study population have been described (18, 19) . Of 242 subjects who were screened, 122 were randomized. Ten subjects dropped out after randomization; three from 5 g/d testosterone arm and seven from 10 g/d testosterone arm. One subject who dropped out was randomized to rhGH placebo, four to 3 g/kg ⅐ d rhGH and five to 5 g/kg ⅐ d rhGH. Of the 112 participants who completed assessments at wk 16, 106 subjects were included in this analysis because serum for P3NP measurement was not available at baseline or during wk 4, 8, or 16 in six subjects.
Baseline characteristics of the 106 participants were typical of community-dwelling, older men without functional limitations (Table 1) (29) . The baseline body mass index (BMI) was 26.2 kg/m 2 , testosterone 363 Ϯ 97 ng/dl, and IGF-I 112 Ϯ 29 ng/dl. The BMI, testosterone, IGF-I, LBM, ASM, VO 2max , or P3NP levels did not differ among groups (Table 1) .
Changes in testosterone and IGF-I levels in HORMA participants have been published (11) . Briefly, treatment with testosterone and rhGH produced dose-related increments in testosterone and IGF-I concentrations. Testosterone levels increased in subjects receiving 5 g/d by 143 Ϯ 379 ng/dl, which was lower (P Ͻ 0.001) than the increase of 510 Ϯ 503 ng/dl in those receiving 10 g/day. For rhGH at 0, 3, and 5 g/kg ⅐ d, levels of IGF-I increased by 6 Ϯ 28 ng/dl (P ϭ 0.15), 64 Ϯ 44 ng/dl (P Ͻ 0.001), and 108 Ϯ 51 ng/dl (P Ͻ 0.001), respectively, with a trend across rhGH dose groups (P Ͻ 0.001).
Changes in body composition have been published (18) . Briefly, in the 106 men who were included in this analysis, LBM and ASM increased significantly from baseline to wk 16 (P Ͻ 0.02) within each of the six groups (18) . The changes in LBM from baseline to wk 16 were higher in men receiving 10 g testosterone gel than in those receiving 5 g testosterone gel. As reported (18) , there was a linear trend across increasing doses of rhGH for increases in LBM.
Baseline serum P3NP concentrations were similar in the six treatment groups (Table 2) . P3NP levels increased during treatment and were significantly higher at wk 4, 8, and 16 compared with baseline. In pairwise comparisons and using Wald trend analysis, the increases in P3NP levels became greater over time (time trend P Ͻ 0.0001) ( Table  2 ). P3NP concentrations were higher during wk 16 than at baseline (P Ͻ 0.0001) or wk 4 (P Ͻ 0.0001) but did not differ from those at wk 8. In men receiving testosterone alone (groups A and D), P3NP levels reached a plateau at wk 4 and did not differ between wk 4 and 8. However, in men treated with testosterone plus any dose of rhGH, wk 8 P3NP levels were significantly higher than wk 4 levels ( Table 2) .
Changes in P3NP from baseline to wk 4, 8, and 16 were significantly correlated with changes in LBM; the highest correlations were observed with LBM change from baseline to wk 16 (r ϭ 0.53, P Ͻ 0.0001) as well as with changes in ASM from baseline to wk 16 (r ϭ 0.40, P Ͻ 0.0001) ( Table 3 and Fig. 1 ) When subjects were categorized into high responders and low responders based on whether the change in LBM from baseline to wk 16 was greater than or less than the median change (1.4 kg), the change in P3NP was significantly higher in the high re- sponders than in the low responders at 4 (P Ͻ 0.004), 8 (P Ͻ 0.001), and 16 (P0.0001) wk, respectively (Table 4) . Similarly, men who experienced more than the median change in ASM demonstrated greater increments in P3NP levels than those who gained less than the median change (Table 4) . By logistic regression, the odds of a greater change in P3NP from baseline to wk 16 were substantially higher in men in the highest quartiles of change in LBM [odds ratio 9.0, 95% confidence interval (CI) 2.6 -31.8] or change in ASM from baseline (odds ratio 4.6, 95% CI 1.4 -15.2) than those in the lowest quartile. Thus, changes in P3NP were strongly associated with changes in LBM and ASM. Importantly, changes in P3NP concentrations from baseline to wk 4 (r ϭ 0.26, P ϭ 007) and wk 8 (r ϭ 0.36, P ϭ 0.0002) were significantly correlated with change in LBM from baseline to wk 16 (Fig. 1C) . Similarly, changes in P3NP concentrations from baseline to wk 4 (r ϭ 0.17, P ϭ 0.07) and 8 (r ϭ 0.25, P ϭ 0.01) were predictive of changes in ASM from baseline to wk 16.
We examined the relationship of P3NP with changes in composite strength of upper-and lower-body muscle groups. In univariate regression analysis, there was a marginal correlation of 0.20 (P ϭ 0.056; Spearman) for change in P3NP at wk 4 and change in composite strength at wk 16. We examined separately the relationship of change in P3NP at wk 4 with changes in composite strength in 39 men who received testosterone alone (study groups A and D); in these men, there was a significant correlation between increases in P3NP at wk 4 and improvements in strength (r ϭ 0.36, P ϭ 0.041).
The changes in P3NP concentrations from baseline to wk 4, 8, and 16 were correlated significantly with changes in testosterone concentrations (Table 3 and Fig. 2A ) from baseline to wk 16. The changes in P3NP levels from baseline to wk 4, 8, and 16 were significantly higher in men who experienced greater increase in testosterone levels (greater than median) than in those who had lesser increase (less than median) ( Table 4) . By logistic regression, odds of greater change in P3NP were significantly higher in men in the highest quartile of change in testosterone levels than those in the lowest quartile of change in testosterone levels (OR 5.3, 3.3, and 2.3 for baseline to wk 4, 8, and 16 change in P3NP).
Changes in P3NP concentrations were also correlated significantly with changes in IGF-I concentrations (Table  3 and Fig. 2B ). The changes in P3NP from baseline to wk 16 were higher in participants who had greater than the median change in IGF-I than in those who had less than the median change (Table 4) . Even more strikingly, men in the highest quartile for IGF-I change had substantially greater likelihood of having greater change in P3NP than those in the lowest quartile (OR 12.9 and 150.0 for high P3NP response from baseline to wk 8 and 16, respectively).
We performed univariate and multivariate regression analyses to examine the determinants of change in P3NP levels from baseline. Baseline BMI, testosterone and IGF-I levels, LBM, and ASM were not significantly associated with either baseline P3NP levels or changes in P3NP levels. Age was inversely related to change in P3NP from baseline to wk 16 in both univariate and multivariate models, after adjusting for baseline BMI, LBM, ASM, testosterone, IGF-I, and change in testosterone and IGF-I. In multivariate analyses, change in IGF-I level from baseline emerged as the most robust predictor of change in P3NP levels, which was significantly associated with change in P3NP (P Ͻ 0.0001), even after adjusting for BMI, age, LBM, ASM, testosterone, and IGF-I, and changes in testosterone and changes in LBM.
The Pearson coefficients of the association of changes in P3NP (r ϭ 0.53, P Ͻ 0.0001) and IGF-I (r ϭ 0.40, P Ͻ 0.0001) with change in LBM were slightly better for P3NP than for IGF-I. To determine the relative ability of the two markers in predicting change in LBM and ASM, we performed stepwise regression using change in LBM or ASM from baseline to wk 16 as the dependent variable and changes in P3NP, IGF-I, age, and change in testosterone levels as independent variables; these independent variables were selected because in univariate analyses, they were correlated with the dependent variable at P Ͻ 0.20. In these models, change in P3NP from baseline to wk 8 or 16 was the strongest predictor of change in LBM and ASM (Table 5 and 6 ). Age and change in testosterone levels added only marginally to the predictive ability of the model and IGF-I did not add significantly to the model (P Ͼ 0.10).
To test for interaction between testosterone and IGF-I relative to the changes in P3NP, we conducted a two-way ANOVA; this analysis revealed a marginal interaction at wk 16 (P ϭ 0.06; data not shown). In the stratified analysis at wk 16, there was a significant effect of testosterone dose in the high IGF-I group (P ϭ 0.01); additionally, IGF-I/ rhGH had significant effects on P3NP at both the high (P ϭ 0.0004) and low testosterone dose (P Ͻ 0.0001).
Because changes in LBM, testosterone, and IGF-I levels are interrelated, we performed linear stepwise regression to determine the relative contribution of each of these variables to the variance of change in P3NP levels. We included change in LBM, IGF-I, and testosterone and age in this model because each of these variables was associated with change in P3NP in univariate analyses with P Ͻ 0.20. In stepwise regression, change in LBM was the best predictor of change in P3NP that alone explained 28% of variance of change in P3NP level. When added after entering change in LBM to the model, change in IGF-I explained 22% of the additional variance in change in P3NP levels, and change in testosterone levels and age were not significant contributors. Similarly, when we used change in ASM as the first variable in stepwise regression model, 16% of variance was explained by this variable. Change in IGF-I explained an additional 31% of the variance, and other variables did not add to the predictive ability of the model.
We sought to determine the magnitude of change in P3NP concentrations that was associated with each kilogram gain in LBM and 0.5 kg gain in ASM; this magnitude of change in P3NP might arguably be deemed the MCID in P3NP concentration. The bootstrapping method revealed that each kilogram change in LBM from baseline to wk 16 was associated with 0.93 ng/ml (95% CI 0.83-1.02) change in P3NP concentration from baseline to wk 16 ( Fig. 3A) and 0.28 ng/ml (95% CI 0.22-0.36) change in P3NP from baseline to wk 4 (Fig. 3B) . Similarly, 0.5 kg change in ASM was associated with 0.57 ng/ml (95% CI 0.57-0.57) change in P3NP from baseline to wk 16 and 0.15 ng/ml (95% CI 0.15-0.16) change from baseline to wk 4.
Discussion
Changes in serum P3NP levels are predictive of changes in total LBM and ASM in community-dwelling older men administered testosterone with or without rhGH. Importantly, changes in P3NP levels at wk 4 were predictive of changes in LBM and ASM at wk 16. Subjects who experienced greater gains in LBM and ASM during testosterone and rhGH administration were more likely to have greater increments in P3NP levels. In stepwise regression models, change in P3NP levels from baseline was the best predictor of changes in LBM and ASM. These data indicate that increases in serum P3NP concentrations may serve as a useful early biomarker of lean To determine the relative contribution of variables that predict change in total lean body mass (LBM) from baseline to wk 16, we performed stepwise regression. The dependent variable (DV) was change in LBM.
The independent variables that were included in the analyses were change in P3NP from baseline to wk 8 (model 1) or change in P3NP from baseline to wk 16 (model 2), change in IGF-I or testosterone levels and age because their adjusted P Ͻ 0.2. P3NP emerged as the strongest predictor of change in the LBM model. IGF-I was not a significant contributor to the models (P Ͼ 0.10) after adjusting for all previously selected variables. *, Partial r 2 is the additional contribution of a variable in predicting change in LBM, adjusting for prior variables in stepwise regression. To determine the relative contribution of variables that predict change in total ASM from baseline to wk 16, we performed stepwise regression. The dependent variable (DV) was change in ASM. The independent variables that were included in the analyses were change in P3NP from baseline to wk 8 (model 1) or change in P3NP from baseline to wk 16 (model 2), change in IGF-I, or testosterone levels and age because their adjusted P Ͻ 0.2. P3NP emerged as the strongest predictor of change in the ASM model. IGF-I was not a significant contributor to the models (P Ͼ 0.10) after adjusting for all previously selected variables. *, Partial r 2 is the additional contribution of a variable in predicting change in LBM, adjusting for prior variables in stepwise regression.
body mass improvements during testosterone supplementation either alone or in combination with rhGH administration.
The time and expense associated with efficacy trials of promyogenic therapies are major retardants in the drug development process. Randomized trials of 6 -12 months duration may be needed to demonstrate efficacy. The availability of robust early predictive biomarkers of an anabolic response would accelerate human studies of anabolic therapies. Ultimately, the efficacy of function promoting anabolic therapies will have to be evaluated in terms of improvements in physical function measures and health outcomes. However, to the extent that promyogenic molecules currently in development, such as testosterone, selective androgen receptor modulators, myostatin antagonists, and rhGH, act primarily by increasing skeletal muscle mass, biomarkers, such as P3NP, that are predictive of subsequent skeletal muscle mass gains could expedite screening of candidate compounds in humans.
In participants receiving only testosterone, increases in P3NP at wk 4 were significantly associated with improvements in composite strength of the major muscle groups in the upper and lower extremities. This suggests that testosterone-induced increases in P3NP reflect subsequent increases in functional myofibrillar proteins and not just general fibrosis or remodeling of other soft lean tissues. It is possible that P3NP increase during rhGH administration may reflect synthesis of nonmyofibrillar proteins or remodeling of other tissues, consistent with the failure of previous rhGH studies to demonstrate muscle strength gains (30 -32) . We recognize that some classes of function promoting therapies, such as vitamin D, may improve physical function by different mechanisms and serum markers of LBM change, such as P3NP, may not be useful biomarkers for those drugs.
Previous studies reported that P3NP levels increase rapidly after administration of rhGH and these elevations in P3NP levels persist for several days after rhGH discontinuation (10, 14) . In our study, serum P3NP levels were significantly elevated above baseline at 4 wk. The men receiving testosterone alone demonstrated a plateau in P3NP levels by wk 4, but the plateau was not reached until wk 8 in those receiving testosterone plus rhGH. Because we did not have a rhGH-alone group, the differences in time course of P3NP response to testosterone and rhGH need confirmation. However, wk 8 and 16 values were not significantly different, suggesting that a plateau had been reached by 8 wk in all men.
P3NP has been explored as a marker of GH doping in athletes (6, 10, 12, 13, 15, 17) and shown to respond to exercise (11) and testosterone (10) . In previous studies, administration of supraphysiological doses of rhGH has been associated with significant elevations of P3NP levels (10), which persisted for 8 wk after GH discontinuation (12) . A multinational team, the GH-2000, has proposed the combined application of IGF-I and P3NP for detection of rhGH doping (13, 15, 16) . P3NP levels rise after a bone fracture or soft tissue muscle injury (9, (33) (34) (35) . P3NP response to rhGH administration may be affected by the age, gender, and stage of pubertal maturation, whereas ethnicity has only a small effect (6, 17, 36) . Our data show that P3NP also increased after testosterone administration in men who did not receive rhGH; thus, the P3NP response is not unique to rhGH. Furthermore, our data provide the first evidence that changes in P3NP are robustly associated with changes in LBM and ASM during testosterone administration with or without rhGH. Similar to the data reported from the GH-2000 study (12) (13) (14) , we found that changes in IGF-I levels were robustly associated with changes in P3NP levels. Because rhGH administration and higher levels of testosterone increase circulating IGF-I levels (37, 38) , it is possible that the effects of both anabolic agents on skeletal muscle might be mediated through IGF-I. The relative roles of testosterone and IGF-I in regulation of circulating P3NP levels should be investigated. We cannot determine from these data whether the changes in P3NP reflect changes in P3NP production or clearance.
P3NP meets many criteria for an early biomarker (39) . It can be measured with precision and accuracy, it responds rapidly to anabolic interventions, early changes in P3NP predict subsequent lean mass acquisition, and there is biological plausibility linking change in P3NP and lean mass acquisition. It is possible that a minimal clinically important difference for change in lean body mass could be predicted from early changes in P3NP. In a metaanalysis, testosterone replacement of androgen-deficient men was associated with about 1.2 kg gain in lean body mass (1) . Similarly, the first-generation trials of selective androgen receptor modulators have revealed 1.0 -1.5 kg increase in LBM during selective androgen receptor modulator administration (40) . In our study, at 16 wk, each kilogram of change in LBM was associated with 0.93 ng/ml increase in P3NP. Thus, P3NP has the characteristics of a potentially valuable biomarker of skeletal muscle mass acquisition in early-phase trials of function promoting anabolic therapies that act by increasing skeletal muscle mass.
